MARKET

RNTX

RNTX

Rein Therapeutics, Inc.
NASDAQ
0.3677
+0.0124
+3.49%
After Hours: 0.3500 -0.0177 -4.81% 19:30 11/19 EST
OPEN
0.3627
PREV CLOSE
0.3553
HIGH
0.4008
LOW
0.3553
VOLUME
1.67M
TURNOVER
--
52 WEEK HIGH
2.100
52 WEEK LOW
0.2844
MARKET CAP
31.72M
P/E (TTM)
-0.2311
1D
5D
1M
3M
1Y
5Y
1D
Rein Therapeutics: Analyst Reiterates Buy and Maintains $4 Price Target Despite Selloff
TipRanks · 1d ago
Rein Therapeutics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Reiterates Buy on Rein Therapeutics, Maintains $8 Price Target
Benzinga · 1d ago
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY), Vor Biopharma (VOR) and Rein Therapeutics (RNTX)
TipRanks · 1d ago
Rein Therapeutics Announces Preliminary Blinded Phase 2 RENEW Data and Reports Third Quarter 2026 Financial Results
NASDAQ · 3d ago
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 3d ago
Rein Therapeutics Updates LTI-03 Program; Phase 2 Topline Results Expected In 2027
NASDAQ · 3d ago
Rein Therapeutics Reports Preliminary Phase 2 RENEW Trial Observations
TipRanks · 3d ago
More
About RNTX
Rein Therapeutics, Inc., formerly Aileron Therapeutics, Inc., is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. The Company's lead product candidate, LTI-03 (idiopathic pulmonary fibrosis), is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Its second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Its pipeline also includes LTI-05 (cystic fibrosis).

Webull offers Rein Therapeutics Inc stock information, including NASDAQ: RNTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNTX stock methods without spending real money on the virtual paper trading platform.